PharmaCyte Biotech
PMCB
PMCB
29 hedge funds and large institutions have $10.2M invested in PharmaCyte Biotech in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
94% less call options, than puts
Call options by funds: $44K | Put options by funds: $756K
Holders
29
Holding in Top 10
1
Calls
$44K
Puts
$756K
Top Buyers
| 1 | +$311K | |
| 2 | +$202K | |
| 3 | +$170K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$137K |
| 5 |
BlackRock
New York
|
+$92.3K |
Top Sellers
| 1 | -$287K | |
| 2 | -$120K | |
| 3 | -$90K | |
| 4 |
Jane Street
New York
|
-$60.7K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$50.3K |